Epilepsy Panel Centogene AG - the Rare Disease Company
Germany | 734 | 744 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Stroke, Cerebral Hemorrhage, Hemiplegia, and Migraine Panel PreventionGenetics, part of Exact Sciences
United States | 345 | 159 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Hyperammonemia Panel PreventionGenetics, part of Exact Sciences
United States | 66 | 63 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Urea Cycle Disorders Panel PreventionGenetics, part of Exact Sciences
United States | 10 | 9 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
ASS1 Sequence Analysis (Prenatal Diagnosis) Baylor Genetics
United States | 1 | 1 | - T Targeted variant analysis
|
ASS1 Sequence Analysis (Familial Mutation/Variant Analysis) Baylor Genetics
United States | 1 | 1 | - T Targeted variant analysis
|
Citrullinemia, Type I via the ASS1 Gene PreventionGenetics, part of Exact Sciences
United States | 1 | 1 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Extended Carrier Screening HNL Genomics Connective Tissue Gene Tests
United States | 44 | 45 | - C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Super Panel Plus NxGen MDx
United States | 116 | 117 | - D Deletion/duplication analysis
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Super Panel 113 NxGen MDx
United States | 113 | 115 | - D Deletion/duplication analysis
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 106 plus TSE Natera, Inc.
United States | 103 | 107 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 27 Natera, Inc.
United States | 28 | 28 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 106 Natera, Inc.
United States | 103 | 106 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 27 plus TSE Natera, Inc.
United States | 28 | 29 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 274 Plus TSE Natera, Inc.
United States | 265 | 275 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 274 Natera, Inc.
United States | 265 | 274 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 137 plus TSE Natera, Inc.
United States | 135 | 138 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 137 Natera, Inc.
United States | 135 | 137 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 274 Natera, Inc.
United States | 265 | 274 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Foresight Myriad Genetics, Inc.
United States | 112 | 110 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
